Medical Economics November 10, 2023
Richard Payerchin

Finance Committee approved wide-ranging legislation this week.

Senate proposals could have good effects on accountable care organizations (ACOs) and pharmacy benefit managers (PBMs), or possibly major pharmaceutical makers, depending on various analyses by health care industry groups.

The National Association of ACOs (NAACOS) and PBM trade associations Transparency-Rx and Pharmaceutical Care Management Association (PCMA) issued statements responding to various elements in the pending legislation titled “The Better Mental Health Care, Lower-Cost Drugs, and Extenders Act.” On Nov. 8, 2023, the Senate Finance Committee voted 26-0 to send the bill for consideration by the full chamber.

ACO incentives

NAACOS President and CEO Clif Gaus, ScD, praised Committee Chair Sen. Ron Wyden (D-Oregon), who was among the legislators commenting on incentives for...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: ACO (Accountable Care), Congress / White House, Govt Agencies, Payment Models, Pharma, Pharma / Biotech, Provider, Value Based
Related Articles:
Medicare Telehealth, Hospital-at-Home Flexibilities In Danger As Partial Government Shutdown Threat Rises
Federal Discretionary Spending To Address Substance Use Disorders: How Big A Shift?
White House and Congress Turn Focus to Health Policy
CVS accused of shutting out rival pharmacy hubs in House Judiciary investigation
OIG Recounts Historic Recovery Numbers in Its Latest Semiannual Report to Congress

Share Article